ScholarIQanswers from OpenAlex & ORCID
Yong Song
ResearcherPublications, citations & collaboration network
Yong Song is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Yong Song have?
ScholarIQindexed works
Yong Song has 561 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Yong Song have?
ScholarIQcitation count
Yong Song has 16,600 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Yong Song?
ScholarIQh-index
Yong Song has an h-index of 66 in OpenAlex.
What is the i10-index of Yong Song?
ScholarIQi10-index
Yong Song has an i10-index of 283 in OpenAlex.
What is the ORCID of Yong Song?
ScholarIQorcid
The ORCID for Yong Song is on the source record.
What is the OpenAlex record for Yong Song?
ScholarIQopenalex
The OpenAlex for Yong Song is on the source record.
What are the most-cited papers on Yong Song?
ScholarIQmost cited works
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi, Li Zhang, Xiaoqing Liu, Caicun Zhou, Li Zhang, Shucai Zhang, Dong Wang, Qiang Li, Shukui Qin, Chunhong Hu, Yiping Zhang, Jianhua Chen, Ying Cheng, Jifeng Feng, Helong Zhang, Yong Song, Yi‐Long Wu, Nong Xu, Jianying Zhou, Rongcheng Luo, Chunxue Bai, Jin Ye-ning, Wenchao Liu, Zhaohui Wei, Fenlai Tan, Yinxiang Wang, Lieming Ding, Hong Dai, Shunchang Jiao, Jie Wang, Li Liang, Weimin Zhang, Yan Sun
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
Yunpeng Yang, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Shundong Cang, Gongyan Chen, Xiaodong Mei, Zhixiong Yang, Rui Ma, Minghong Bi, Xiubao Ren, Jianying Zhou, Baolan Li, Yong Song, Jifeng Feng, Juan Li, Zhiyong He, Rui Zhou, Weimin Li, You Lü, Yingyi Wang, Lijun Wang, Nong Yang, Yan Zhang, Zhuang Yu, Yanqiu Zhao, Conghua Xie, Ying Cheng, Hui Zhou, Shuyan Wang, Donglei Zhu, Wen Zhang, Li Zhang
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
Yuankai Shi, L. Wang, Baohui Han, W. Li, Pei-wu Yu, Y.P. Liu, Chunming Ding, Xia Song, Z.Y. Ma, Xiaowen Ren, J. Feng, H. L. Zhang, G. -Y. Chen, Xiaohong Han, Ning Wu, Chia-Yu Yao, Yong Song, S. C. Zhang, Wei Song, X. Q. Liu, Sha Zhao, Yangxuan Lin, X.Q. Ye, K. Li, Yongqian Shu, Lili Ding, F. Tan, Yan Sun
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
Qing Zhou, Chong‐Rui Xu, Ying Cheng, Yunpeng Liu, Gongyan Chen, Jiuwei Cui, Nong Yang, Yong Song, Xiaoling Li, Shun Lü, Jianying Zhou, Zhiyong Ma, Shiying Yu, Cheng Huang, Yongqian Shu, Zhen Wang, Jin‐Ji Yang, Hai‐Yan Tu, Wen‐Zhao Zhong, Yi‐Long Wu
Icotinib versus whole-brain irradiation in patients with EGFR -mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial
Jin‐Ji Yang, Caicun Zhou, Yi-Sheng Huang, Jifeng Feng, Lu Sun, Yong Song, Cheng Huang, Gang Wu, Li Zhang, Ying Cheng, Chengping Hu, Gongyan Chen, Li Zhang, Xiaoqing Liu, Hong Yan, Fen Lai Tan, Wen‐Zhao Zhong, Yi‐Long Wu